AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14985946 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak vBMD at the lumbar spine
Number of subjects: 266
Study 14985946 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak vBMD at the femoral neck
Number of subjects: 266
Study 14985946 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak vBMD at the UDR
Number of subjects: 266
Study 14985946 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone size during consolidation
Number of subjects: 266
Study 10763787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluids prepared using a viscometer
Number of subjects: 23
Study 10763787 — intervention group
Group type: COMPARATOR
Intervention: Fluids prepared subjectively by nursing staff
Number of subjects: 23
Study 10763787 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 23
Study 8833170 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 23
Study 8833170 — intervention group
Group type: COMPARATOR
Intervention: Injective immunotherapy (SIT)
Number of subjects: 23
Study 1579515 — intervention group
Group type: EXPERIMENTAL
Intervention: Food additives (tartrazine and benzoates) confirmed with diet and double blind challenge
Number of subjects: 2
Study 6391562 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 52
Study 6391562 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation (noncultic)
Number of subjects: 52
Study 6391562 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 52
Study 3830240 — intervention group
Group type: EXPERIMENTAL
Intervention: FCE20700 (1 mg, 2 mg)
Number of subjects: 6
Study 3830240 — intervention group
Group type: EXPERIMENTAL
Intervention: FCE20700 (2 mg)
Number of subjects: 6
Study 3830240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31962003 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (group A)
Number of subjects: 75
Study 31962003 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 75
Study 29722834 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric sweeteners (50 g glucose and 25 g fructose)
Number of subjects: 12
Study 29722834 — intervention group
Group type: COMPARATOR
Intervention: Noncaloric sweetener (220 mg acesulfame-K)
Number of subjects: 12
Study 26494130 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat in combination with bortezomib and dexamethasone
Number of subjects: 12
Study 26494130 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat (MTD)
Number of subjects: 12
Study 26494130 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat exposure
Number of subjects: 12
Study 26494130 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat with dexamethasone
Number of subjects: 12
Study 26494130 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat without dexamethasone
Number of subjects: 12
Study 26494130 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat single-agent trials
Number of subjects: 12
Study 24633858 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia Education Programme Incorporating Reminiscence for Staff
Number of subjects: 0
Study 22168539 — intervention group
Group type: EXPERIMENTAL
Intervention: Ostim
Number of subjects: 14
Study 22168539 — intervention group
Group type: COMPARATOR
Intervention: Natural healing (Control)
Number of subjects: 14
Study 20096638 — intervention group
Group type: EXPERIMENTAL
Intervention: Depotestosterone + Anastrozole (T-A)
Number of subjects: 40
Study 20096638 — intervention group
Group type: COMPARATOR
Intervention: Depotestosterone + Placebo (T-P)
Number of subjects: 40
Study 20096638 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study 19142476 — intervention group
Group type: EXPERIMENTAL
Intervention: Information with previous delivery of emergency contraception (Medicated Group)
Number of subjects: 823
Study 19142476 — intervention group
Group type: COMPARATOR
Intervention: Information only (Control Group)
Number of subjects: 823
Study 19142476 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicated Group
Number of subjects: 823
Study 19142476 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 823
Study 16895639 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) pretreatment with recombinant human FSH (r-hFSH) starting on day 2 or 3 after OC withdrawal.
Number of subjects: 64
Study 16895639 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving r-hFSH starting on day 2 of a natural cycle.
Number of subjects: 64
Study 14517771 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive cyclists
Number of subjects: 42
Study 14517771 — intervention group
Group type: COMPARATOR
Intervention: Ex-cyclists
Number of subjects: 42
Study 14517771 — intervention group
Group type: EXPERIMENTAL
Intervention: Active sportsmen
Number of subjects: 42
Study 14517771 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive cycling
Number of subjects: 42
Study 11030186 — intervention group
Group type: EXPERIMENTAL
Intervention: Creon
Number of subjects: 60
Study 11030186 — intervention group
Group type: COMPARATOR
Intervention: Pancrease
Number of subjects: 60
Study 8752186 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg once daily
Number of subjects: 459
Study 8752186 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg once daily
Number of subjects: 459
Study 8752186 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg twice daily
Number of subjects: 459
Study 8752186 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg twice daily
Number of subjects: 459
Study 8752186 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 459
Study 8752186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459
Study 1373779 — intervention group
Group type: COMPARATOR
Intervention: Finasteride (5 to 80 mg per day) for 12 weeks
Number of subjects: 190
Study 1373779 — intervention group
Group type: COMPARATOR
Intervention: Finasteride (0.2 to 40 mg per day) for 24 weeks
Number of subjects: 190
Study 1373779 — intervention group
Group type: COMPARATOR
Intervention: Finasteride (1 and 5 mg groups combined)
Number of subjects: 190
Study 1373779 — intervention group
Group type: COMPARATOR
Intervention: Finasteride (1 and 5 mg groups)
Number of subjects: 190
Study 4040050 — intervention group
Group type: EXPERIMENTAL
Intervention: Reglan
Number of subjects: 0
Study 4040050 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Reglan and Solu‐medrol
Number of subjects: 0
Study 4040050 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 30676135 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO + PRO (protein from beef and whey mixed with orange juice)
Number of subjects: 25
Study 30676135 — intervention group
Group type: COMPARATOR
Intervention: CHO (nonprotein isoenergetic carbohydrate)
Number of subjects: 25
Study 30676135 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO + PRO
Number of subjects: 25
Study 30676135 — intervention group
Group type: COMPARATOR
Intervention: CHO
Number of subjects: 25
Study 29796851 — intervention group
Group type: EXPERIMENTAL
Intervention: Esoxx® (hyaluronic acid and chondroitin sulfate)
Number of subjects: 50
Study 29796851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 27820821 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue interventions (DEN)
Number of subjects: 1301
Study 27820821 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined diarrhea and dengue interventions (DIADEN)
Number of subjects: 1301
Study 27820821 — intervention group
Group type: EXPERIMENTAL
Intervention: Diarrhea interventions (DIA)
Number of subjects: 1301
Study 27820821 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 1301
Study 25317619 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate solution (3 ml/kg of sodium bicarbonate solution (150 mEq/L) one hour prior to procedure and then drip rate decreased to 1 ml/kg/hour until 6 hours post procedure)
Number of subjects: 220
Study 25317619 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride solution (1 ml/kg/hour of normal saline solution, starting 12 hours before and continuing 12 hours after iohexol contrast)
Number of subjects: 220
Study 22360500 — intervention group
Group type: EXPERIMENTAL
Intervention: Palindrome catheter (PC)
Number of subjects: 97
Study 22360500 — intervention group
Group type: COMPARATOR
Intervention: Step-tip catheter (SC)
Number of subjects: 97
Study 19602993 — intervention group
Group type: EXPERIMENTAL
Intervention: Light protected parenteral nutrition
Number of subjects: 40
Study 19602993 — intervention group
Group type: COMPARATOR
Intervention: Light exposed parenteral nutrition
Number of subjects: 40
Study 19083385 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine supplementation (4.5 g x d(‐1))
Number of subjects: 0
Study 19083385 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4.5 g x d(‐1) of maltodextrin)
Number of subjects: 0
Study 16463921 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional cash transfers
Number of subjects: 0
Study 16463921 — intervention group
Group type: COMPARATOR
Intervention: Existing family and community migration networks
Number of subjects: 0
Study 12514675 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise training (20 minutes of ergometry training per day and 1 group training session per week for 5 months after 4 weeks of in-hospital training).
Number of subjects: 19
Study 12514675 — intervention group
Group type: COMPARATOR
Intervention: In-hospital exercise training (60 minutes of bicycle ergometry per day for 4 weeks).
Number of subjects: 19
Study 11078903 — intervention group
Group type: EXPERIMENTAL
Intervention: Older females (9)
Number of subjects: 17
Study 11078903 — intervention group
Group type: COMPARATOR
Intervention: Young females (8)
Number of subjects: 17
Study 11078903 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (young and older)
Number of subjects: 17
Study 8720611 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial 2-h post-load plasma glucose levels
Number of subjects: 158
Study 8720611 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting proinsulin levels
Number of subjects: 158
Study 8720611 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric characteristics, 2-h post-load specific insulin levels, fasting proinsulin/fasting insulin ratio
Number of subjects: 158
Study 8720611 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of NIDDM
Number of subjects: 158
Study 1359258 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (2.5‐20 mg per day)
Number of subjects: 6797
Study 3994881 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichloroethylene (0.2 or 0.3 vol.%)
Number of subjects: 777
Study 3994881 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (0.2, 0.3, 0.4 or 0.5 vol.%)
Number of subjects: 777
Study 3994881 — intervention group
Group type: COMPARATOR
Intervention: Lower concentrations of volatile agents
Number of subjects: 777
Study 3994881 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichloroethylene 0.3 vol.% or halothane 0.4 or 0.5 vol.%
Number of subjects: 777
Study 3994881 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichloroethylene and halothane at recommended concentrations
Number of subjects: 777
Study 3994881 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichloroethylene and halothane in cases of fetal compromise
Number of subjects: 777
Study 3994881 — intervention group
Group type: EXPERIMENTAL
Intervention: Breech presentation and prolongation of the U‐D interval
Number of subjects: 777
Study 30957065 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Number of subjects: 23
Study 29917038 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 329
Study 29917038 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and vegetables diet
Number of subjects: 329
Study 29917038 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 329
Study 27871699 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME) with a bonded acrylic expander
Number of subjects: 36
Study 27871699 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 36
Study 27871699 — intervention group
Group type: EXPERIMENTAL
Intervention: RME group
Number of subjects: 36
Study 25122121 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 400 mg tribendimidine
Number of subjects: 156
Study 25122121 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg tribendimidine twice daily
Number of subjects: 156
Study 25122121 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg/kg praziquantel divided in four doses within 2 days
Number of subjects: 156
Study 25122121 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 400 mg mebendazole
Number of subjects: 156
Study 21748413 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple Vote ensemble classifier
Number of subjects: 77495
Study 21748413 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted Vote ensemble classifier
Number of subjects: 77495
Study 21748413 — intervention group
Group type: COMPARATOR
Intervention: Individual classifiers
Number of subjects: 77495
Study 21098435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 509
Study 21098435 — intervention group
Group type: COMPARATOR
Intervention: RFCA
Number of subjects: 509
Study 18674471 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/d atorvastatin
Number of subjects: 10001
Study 18674471 — intervention group
Group type: COMPARATOR
Intervention: 10 mg/d atorvastatin
Number of subjects: 10001
Study 16438370 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaxigrip vaccine
Number of subjects: 125
Study 16438370 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbidol
Number of subjects: 125
Study 16438370 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Vaxigrip and Arbidol
Number of subjects: 125
Study 16438370 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 125
Study 12721777 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg)
Number of subjects: 48
Study 12721777 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (50 mg)
Number of subjects: 48
Study 12721777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 10863494 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Smiles, Bright Future curriculum
Number of subjects: 0
Study 10863494 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 8719072 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue exertion on fluid-filled bulb, exerting from 10 to 100% of maximal effort in 10% increments.
Number of subjects: 20
Study 8719072 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand exertion on fluid-filled bulb, exerting from 10 to 100% of maximal effort in 10% increments.
Number of subjects: 20
Study 2331082 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 2331082 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone and halothane
Number of subjects: 20
Study 6446446 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole
Number of subjects: 0
Study 6446446 — intervention group
Group type: COMPARATOR
Intervention: Oxytetracycline
Number of subjects: 0
Study 29917115 — intervention group
Group type: EXPERIMENTAL
Intervention: iPad-based cognitive rehabilitation program (3 hours per week for 10 weeks)
Number of subjects: 0
Study 29917115 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (no intervention during the study period)
Number of subjects: 0
Study 27564431 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPID3 remission (score ≤3)
Number of subjects: 690
Study 27564431 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPID3 + 1 SJC (score ≤3 + 1 swollen joint)
Number of subjects: 690
Study 27564431 — intervention group
Group type: EXPERIMENTAL
Intervention: SDAI remission (score ≤3.3)
Number of subjects: 690
Study 27564431 — intervention group
Group type: EXPERIMENTAL
Intervention: Boolean remission (all ≤1)
Number of subjects: 690
Study 25947165 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with recombinant viral vectors chimpanzee adenovirus 63 (ChAd63) and modified vaccinia Ankara (MVA) encoding ME-TRAP.
Number of subjects: 121
Study 25947165 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell responses to TRAP peptides 21 to 30.
Number of subjects: 121
Study 25947165 — intervention group
Group type: COMPARATOR
Intervention: Rabies vaccine (control).
Number of subjects: 121
Study 24078508 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (2 mg at night for two weeks, increasing to 4 mg for a further two weeks)
Number of subjects: 31
Study 24078508 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal desmopressin (20 μg at night)
Number of subjects: 31
Study 24078508 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 31
Study 24078508 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal desmopressin
Number of subjects: 31
Study 21491106 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Phe load (100 mg/kg body weight) administered to PKU patients prior to one fMRI session (placebo-controlled)
Number of subjects: 17
Study 21491106 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 17
Study 21491106 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Phe load (100 mg/kg body weight)
Number of subjects: 17
Study 19430718 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy of pancreas
Number of subjects: 39
Study 19430718 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy of gastric mucosa
Number of subjects: 39
Study 19430718 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy of liver
Number of subjects: 39
Study 19430718 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy of bile duct
Number of subjects: 39
Study 19430718 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy of duodenal papilla
Number of subjects: 39
Study 19430718 — intervention group
Group type: COMPARATOR
Intervention: Biopsy of gastric mucosa in pancreatic cancer patients (control group)
Number of subjects: 39
Study 16352812 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 586
Study 16352812 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 586
Study 15197438 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 128
Study 15197438 — intervention group
Group type: COMPARATOR
Intervention: Invasive mechanical ventilation (Control)
Number of subjects: 128
Study 15197438 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV (successful cases)
Number of subjects: 128
Study 15197438 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV (failed cases)
Number of subjects: 128
Study 11195719 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ms SOA with target from the same location as the cue
Number of subjects: 0
Study 11195719 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 ms SOA with target and cue from different locations
Number of subjects: 0
Study 11195719 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual task with eye movements required (Experiment 3)
Number of subjects: 0
Study 11195719 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual task without eye movements (Experiment 2)
Number of subjects: 0
Study 9252775 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% tretinoin
Number of subjects: 6
Study 9252775 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% beta-lipohydroxyacid
Number of subjects: 6
Study 9252775 — intervention group
Group type: COMPARATOR
Intervention: 5% salicylic acid
Number of subjects: 6
Study 9252775 — intervention group
Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 6
Study 7543781 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 14
Study 7543781 — intervention group
Group type: COMPARATOR
Intervention: Control group (no G-CSF)
Number of subjects: 14
Study 2655681 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide 10 mg
Number of subjects: 9
Study 2655681 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide 100 mg
Number of subjects: 9
Study 2655681 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide 2.5 mg
Number of subjects: 9
Study 2655681 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide 250 micrograms
Number of subjects: 9
Study 2655681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 319892 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary additive hormone therapy followed by adrenalectomy
Number of subjects: 226
Study 319892 — intervention group
Group type: COMPARATOR
Intervention: Primary adrenalectomy followed by chemotherapy and/or additive hormone therapy
Number of subjects: 226
Study 319892 — intervention group
Group type: EXPERIMENTAL
Intervention: Oophorectomy followed by adrenalectomy
Number of subjects: 226
Study 319892 — intervention group
Group type: COMPARATOR
Intervention: Adrenalectomy-oophorectomy as primary mode of therapy
Number of subjects: 226
Study 319892 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential hormonal manipulation
Number of subjects: 226
Study 319892 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary adrenalectomy
Number of subjects: 226
Study 30803143 — intervention group
Group type: EXPERIMENTAL
Intervention: DSEK
Number of subjects: 74
Study 30803143 — intervention group
Group type: COMPARATOR
Intervention: DSAEK
Number of subjects: 74
Study 28575496 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (r‐ESWT)
Number of subjects: 54
Study 28575496 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) therapy
Number of subjects: 54
Study 28575496 — intervention group
Group type: COMPARATOR
Intervention: Control group (home exercises only)
Number of subjects: 54
Study 25858976 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention
Number of subjects: 3602
Study 25858976 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting
Number of subjects: 3602